Regeneron (REGN) – Business Wire
-
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
-
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
-
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
-
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron
-
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
-
Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
-
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual) – Friday, November 13, 2020
-
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual)
Back to REGN Stock Lookup